An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen(BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
C-CAR168 represents a novel bi-specific CAR-T therapy targeting both CD20 and BCMA, aimed at treating central nervous system autoimmune diseases that are refractory to standard therapies. The market for such therapies is expanding, particularly as existing treatments often fail to provide adequate relief for patients with conditions like Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorders (NMOSD). The competitive landscape includes other CAR-T therapies and emerging biologics targeting similar pathways. Given the high unmet need in this patient population, successful outcomes could position C-CAR168 favorably in a niche but growing market. Diligence should focus on the safety profile and efficacy data emerging from this trial, as these will be critical for future investment and partnership opportunities.
Indication: Multiple Sclerosis (MS)
Modality: cell therapy
Target: CD20 and B-cell Maturation Antigen (BCMA)
Sponsor: Huashan Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 25, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD20 and B-cell Maturation Antigen (BCMA)
View original source fields
Condition raw: Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
Condition normalized: Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CD20 and B-cell Maturation Antigen (BCMA)
Target normalized: CD20 and B-cell Maturation Antigen (BCMA)